Sunday, September 24, 2017

DUBLIN, Sept. 22, 2017 /PRNewswire/ -- Allergan plc (NYSE: AGN) today announced that it received a Refusal to File (RTF) letter from the U.S. Food and Drug Administration (FDA) regarding its Supplemental New Drug Application (sNDA) for Vraylar (cariprazine) for treatment of negative symptoms associated with schizophrenia in a.....   [READ MORE]
LONDON, September 22, 2017 /PRNewswire/ --   [READ MORE]

About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines